...
首页> 外文期刊>Science translational medicine >Plasmacytoid Dendritic Cells, Interferon Signaling, and FcgammaR Contribute to Pathogenesis and Therapeutic Response in Childhood Immune Thrombocytopenia
【24h】

Plasmacytoid Dendritic Cells, Interferon Signaling, and FcgammaR Contribute to Pathogenesis and Therapeutic Response in Childhood Immune Thrombocytopenia

机译:浆细胞样树突状细胞,干扰素信号和FcgammaR有助于儿童免疫性血小板减少症的发病机理和治疗反应。

获取原文
获取原文并翻译 | 示例
           

摘要

Immune thrombocytopenia (ITP) is an autoimmune disorder of childhood characterized by immune-mediated destruction of platelets. The mechanisms underlying the pathogenesis of ITP and the therapeutic efficacy of intravenous immunoglobulins (IVIG) in this disorder remain unclear. We show that monocytes from patients with ITP have a distinct gene expression profile, with increased expression of type I interferon response (IR) genes. Plasma from ITP patients had increased levels of several cytokines indicative of immune activation, including an increase in interferon-a. ITP patients also had an increase in plasmacytoid dendritic cells (pDCs) compared to healthy donors. Therapy-induced ?remission of ITP was associated with abrogation of the IR gene signature in monocytes without reduction in the levels of circulating interferon-a itself. IVIG altered the ratio of activating/inhibitory Fcgamma receptors (FcgammaRs) in vivo primarily by reducing FcyRIII (CD16). The engagement of activating FcyRs was required for IVIG-mediated abrogation of monocyte response to exogenous interferon-a in culture. Moreover, plasma from ITP patients led to activation of monocytes and myeloid DCs in culture with an increase in T cell stimulatory capacity; this activation depended on the engagement of activating FcyRs and interferon-a receptor (IFNAR) and was inhibited by antibody-mediated blockade of these pathways. These data point to a central role of type I interferon in the pathogenesis of ITP and suggest targeting pDCs and blockade of IR as potential therapeutic approaches in this disorder. They also provide evidence for the capacity of IVIG to extinguish IR in vivo, which may contribute to its effects in autoimmunity.
机译:免疫性血小板减少症(ITP)是儿童期的自身免疫性疾病,其特征在于免疫介导的血小板破坏。尚不清楚ITP发病机理的基础以及该疾病中静脉免疫球蛋白(IVIG)的治疗功效。我们显示,来自ITP患者的单核细胞具有独特的基因表达谱,其中I型干扰素应答(IR)基因表达增加。来自ITP患者的血浆中几种指示免疫激活的细胞因子水平升高,包括干扰素-a升高。与健康供体相比,ITP患者的浆细胞样树突状细胞(pDC)也有所增加。治疗诱导的ITP缓解与单核细胞中IR基因标记的消除有关,而不会降低循环干扰素-α本身的水平。 IVIG主要通过减少FcyRIII(CD16)来改变体内激活/抑制性Fcgamma受体(FcgammaRs)的比例。 IVIG介导的废除单核细胞对培养物中外源性干扰素-α的反应需要激活的FcyRs参与。此外,ITP患者的血浆导致培养物中单核细胞和髓样DC的激活,并增加了T细胞的刺激能力。这种活化取决于活化的FcγR和干扰素-α受体(IFNAR)的参与,并被抗体介导的这些途径的阻断所抑制。这些数据表明I型干扰素在ITP的发病机制中起着核心作用,并提示靶向pDC和阻断IR是该疾病的潜在治疗方法。它们还提供了IVIG在体内消除IR的能力的证据,这可能有助于其在自身免疫中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号